United
Kingdom Cell & Gene Therapy Cold Chain Logistics market is anticipated to
grow significantly rate in the projected period of 2028 due
to increasing demand for cell and gene therapies, development of advanced cold
chain technologies and solutions, supportive regulatory environment &
government initiatives, and presence of a strong research and innovation
ecosystem.
The cell and gene therapy cold chain logistics market in the
United Kingdom has been experiencing significant growth due to the increasing
number of clinical trials and approvals for cell and gene therapies. As of 6th
May 2023 there are around 23,372 clinical trials in different phases of
development across the United Kingdom. The United Kingdom has been a
pioneer in this field, with the country being the first to approve a gene
therapy for a genetic disease in 2012. The growth of the cell and gene therapy
market has created a need for specialized logistics services to maintain the
integrity of these complex therapies during transportation. Cold chain
logistics is crucial for the safe and effective delivery of cell and gene
therapies, as they require specific temperature and humidity conditions to
maintain their stability and potency.
There are several companies operating in the United Kingdom
that specialize in cold chain logistics for cell and gene therapies, including
DHL, World Courier, and Biocair. These companies offer a range of services,
including temperature-controlled packaging, transport, storage, and monitoring.
In 2021, the United Kingdom government also announced a USD 11 million
investment to establish a new Cell and Gene Therapy Catapult Innovation Centre
in Stevenage, United Kingdom which will provide state-of-the-art facilities
for the development and commercialization of advanced therapies. This
investment is expected to further drive growth in the cell and gene therapy
market and the associated logistics services, thereby supporting the growth of
United Kingdom cell & gene therapy cold chain logistics market. Thus,
such favorable environment for innovation and growing demand is anticipated to push
the United Kingdom cell & gene therapy cold chain logistics market.
Development of Advanced Cold Chain Technologies and Solutions
is a Factor that Driving the Market Growth
United Kingdom cell and gene therapy cold chain logistics
market is experiencing significant growth, due to the growing demand for cell
therapies. Cell therapies involve the use of living cells to treat various diseases,
including cancer and genetic disorders. The logistics associated with these
therapies are critical to ensure their safe and effective delivery to patients.
The demand for cell therapies has been steadily increasing in recent years due
to their promising results in clinical trials. In the United Kingdom, there has
been a significant increase in the number of clinical trials for cell
therapies, which has led to the approval of several cell-based products for
commercial use. According to clinicaltrials.gov, there are around 610
studies in different phases of development related to cell therapies in the
United Kingdom.
The logistics associated with cell therapies are complex and
require specialized infrastructure to ensure their safe and efficient transportation.
Cold chain logistics is essential for maintaining the viability and potency of
these therapies during transportation. This process involves maintaining a
specific temperature range throughout the entire supply chain, from production
to delivery.
United Kingdom cell and gene therapy cold chain logistics
market growth is supported by several companies that specialize in providing
these services. These companies offer a range of services, including
temperature-controlled packaging, transport, storage, and monitoring. They use
advanced technologies to ensure that the cell therapies remain at the required
temperature throughout the entire supply chain. The growing demand for cell
therapies has also led to increased investment in the United Kingdom's cell and
gene therapy sector. The continuous investment in the gene and therapy sector
by United Kingdom government can increase its uneven share of the global gene
and therapy market to 15% which equates to more than USD 11 billion of revenue (predominately
exports) and 18,000 jobs in 2035.
The investment in the United Kingdom cell and gene therapy
sector is expected to drive growth in the associated logistics services,
including cold chain logistics. As more cell therapies are developed and
approved for commercial use, the demand for specialized logistics services will
continue to grow. In addition to the growth of the cell and gene therapy
sector, the COVID-19 pandemic has also contributed to the increased demand for cold
chain logistics services. The pandemic has highlighted the importance of safe
and efficient vaccine distribution, which requires specialized logistics
services to maintain the integrity of the vaccines during transportation. Thus,
all the above-mentioned advancement is expected to drive the growth of the United
Kingdom cell & gene therapy cold chain logistics market.
Supportive Regulatory Environment and Government Initiatives is
Pushing Cell & Gene Therapy Cold Chain Logistics Market Growth
United Kingdom cell and gene therapy cold chain logistics
market is expected to see significant growth in the coming years, on account of
the supportive regulatory environment and government initiatives. The United Kingdom
has established itself as a global leader in cell and gene therapy research and
development, and the government has taken several steps to support the growth
of this sector, including initiatives to promote innovation and investment in industry.
The United Kingdom has a robust regulatory framework in place that provides a
clear path to market for these therapies. The Medicines and Healthcare Products
Regulatory Agency (MHRA) is responsible for regulating cell and gene therapies
in the United Kingdom, and it has established a dedicated team to support the
development and approval of these therapies.
The MHRA has also introduced several initiatives to promote
the development of cell and gene therapies in the United Kingdom. For instance,
United Kingdom has established the Accelerated Access Pathway (AAP), which
provides a streamlined regulatory process for innovative therapies that address
unmet medical needs. This initiative helps to speed up the development and
approval process for cell and gene therapies, enabling them to reach patients
more quickly.
The United Kingdom government has also taken several steps to
support the growth of the cell and gene therapy industry. In 2018, the
government announced the Life Sciences Sector Deal, which included a USD 1.46 billion
investment in the sector. This investment is intended to support the development
of innovative therapies and technologies, including cell and gene therapies, genomics,
and AI-powered diagnosis.
The government has also established the Cell and Gene Therapy
Catapult, a center of excellence for the development and commercialization of
cell and gene therapies. Catapult provides state-of-the-art facilities and
expertise to support the development of these therapies and has helped to
position the United Kingdom as a global leader in the industry.
The supportive regulatory environment and government
initiatives are expected to propel the growth of the United Kingdom's cell and
gene therapy cold chain logistics market. The logistics associated with these
therapies are complex and require specialized infrastructure to ensure their
safe and efficient transportation. Cold chain logistics is essential for
maintaining the viability and potency of these therapies during transportation.
As the United Kingdom cell and gene therapy cold chain logistics market are
supported by several companies that specialize in providing these services.
These companies offer a range of services, including temperature-controlled
packaging, transport, storage, and monitoring. They use advanced technologies
to ensure that the cell therapies remain at the required temperature throughout
the entire supply chain.
Technological Advancements are Key Reason that Responsible for
Market Growth
United Kingdom cell and gene therapy cold chain logistics
market is continuously evolving due to technological advancements that are transforming
the industry. With the increasing demand for cell and gene therapies, it is
essential to have efficient and safe logistics processes to transport these
therapies. The use of advanced technologies has become a significant trend in
the industry, allowing for the optimization of logistics processes and the
reduction of risks associated with transportation.
The latest trends in the United Kingdom's cell and gene
therapy cold chain logistics market are the use of automation and robotics
in logistics processes. The use of automated systems and robotics has
enabled logistics providers to improve their efficiency and accuracy in
handling sensitive and valuable materials. The technology reduces the risk of
human error, ensures consistency in processes, and enables faster turnaround
times.
The adoption of real-time monitoring and tracking
technologies is major trend in the United Kingdom's cell and gene therapy cold
chain logistics market. The use of temperature sensors and other monitoring
devices enables logistics providers to track the location and temperature of
cell and gene therapies throughout the transportation process. The technology
helps to ensure that the therapies are transported within the required
temperature range, and in case of any deviations, the logistics providers can
take corrective actions quickly.
The increasing adoption of cloud-based logistics
management systems is also a trend in the United Kingdom's cell and gene
therapy cold chain logistics market. These systems provide real-time visibility
of logistics processes, allowing logistics providers to monitor the status of
the transportation process in real-time. The technology enables efficient
collaboration and communication between different stakeholders involved in the
logistics processes, including the logistics providers, hospitals, and pharmaceutical
companies.
The use of blockchain technology is another key trend
in the United Kingdom's cell and gene therapy cold chain logistics market. The
technology enables secure and transparent record-keeping of logistics
processes. It helps to ensure the authenticity of the transportation process,
ensuring that the therapies are not tampered with during transportation. The
use of blockchain technology can also help to reduce the risk of counterfeiting
and ensure the safety of patients.
The use of artificial intelligence (AI) and machine
learning (ML) is also a trend in the United Kingdom's cell and gene therapy
cold chain logistics market. The technology enables logistics providers to
predict and identify potential transportation issues before they occur,
enabling them to take corrective actions proactively. The technology can also
help to optimize logistics processes, reducing transportation costs and
improving efficiency.
Download Free Sample Report
Market Segmentation
United
Kingdom Cell & Gene Therapy Cold Chain Logistics market is segmented based on component,
services offered, mode sof transportation, holding temperature range, end user, and region. Based on the component, the market is divided into cryogenic
shippers, cryogenic storage freezers, ultra-low freezers, cold chain management
systems, shipment and storage medium, cryogenic pack out kits, and others
{shipment containers, reusable boxes, etc.}. Based on the service
offered, the market is divided into transportation, storage, and packaging. Based on the mode of transportation,
the market is divided into air, ground, and water. Based
on the holding temperature range, the market is divided into cryogenic,
refrigerated, ambient, and others {deep freezers, dry ice, etc.}. Based on the end
user, the market is divided into pharmaceutical & biotechnology companies,
academic & research institutes, and others.
Company Profiles
Atelerix Ltd., Life Science Group Ltd (LSG), Arvato
Group, DGP Intelius Ltd., QuickSTAT (A Kuehne + Nagel Company), BIOCAIR,
TrakCel, Cryoport UK Limited, Patheon UK Limited (Thermo Fischer Scientific
UK), Catalent UK are some of the key players of United
Kingdom cell & gene therapy cold chain logistics market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, Volume in tons and CAGR for 2018-2022 and
2023-2028
|
|
Report coverage
|
Revenue forecast, volume
forecasting, Company shares, competitive landscape, growth factors, and trends
|
|
Segments
covered
|
Component
Services
Offered
Mode
of Transportation
Holding
Temperature Range
End
User
|
|
Country scope
|
Scotland, South-East,
London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands
|
|
Key companies profiled
|
Atelerix Ltd., Life Science Group Ltd
(LSG), Arvato Group, DGP Intelius Ltd., QuickSTAT (A Kuehne + Nagel Company),
BIOCAIR, TrakCel, Cryoport UK Limited, Patheon UK Limited (Thermo Fischer
Scientific UK), Catalent UK
|
|
Customization
scope
|
10% free report customization with purchase. Addition or alteration
to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase
options to meet your exact research needs.
|
|
Delivery
Format
|
PDF and Excel through Email (We can
also provide the editable version of the report in PPT/Word format on special
request)
|
Report Scope:
In this report, United Kingdom Cell & Gene Therapy Cold
Chain Logistics market has been segmented into the following categories, in addition
to the industry trends, which have also been detailed below:
- United Kingdom Cell & Gene Therapy Cold
Chain Logistics Market, By Component:
- Cryogenic Shippers
- Cryogenic Storage Freezers
- Ultra Low Freezers
- Cold Chain Management Systems
- Shipment and Storage Medium
- Cryogenic Packout Kits
- Others include shipment containers, reusable
boxes, etc.
- United
Kingdom Cell & Gene Therapy Cold Chain Logistics Market, By Services Offered:
- Transportation
- Storage
- Packaging
- United
Kingdom Cell & Gene Therapy Cold Chain Logistics Market, By Mode of Transportation:
- United
Kingdom Cell & Gene Therapy Cold Chain Logistics Market, By Holding Temperature Range:
- Cryogenic
- Refrigerated
- Ambient
- Others
include deep freezers, dry ice, etc.
- United
Kingdom Cell & Gene Therapy Cold Chain Logistics Market, By End User:
- Pharmaceutical
& Biotechnology Companies
- Academic
& Research Institutes
- Others
- United Kingdom Cell & Gene Therapy Cold
Chain Logistics Market, By Region:
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire & Humberside
- East Midlands
Competitive landscape
Company Profiles: Detailed analysis of the major companies in United
Kingdom Cell & Gene Therapy Cold Chain Logistics market.
Available Customizations:
With the
given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
United Kingdom Cell &
Gene Therapy Cold Chain Logistics Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]